CoreValve® System Australia/New Zealand Clinical Study
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To evaluate the performance, efficacy and safety of the percutaneous implantation of the CoreValve® prosthetic aortic valve in patients with severe symptomatic native aortic valve stenosis that have an elevated surgical risk
| Condition | Intervention |
|---|---|
|
Aortic Valve Stenosis |
Device: Medtronic CoreValve® System |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | CoreValve® System Australia/New Zealand Clinical Study |
- Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) rate and Cardiac Death [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Freedom from Conversion to Surgery [ Time Frame: 30 Days, 6, 12, 24 months ] [ Designated as safety issue: Yes ]
- Freedom from MACCE [ Time Frame: 30 days, 6, 12, 24 months ] [ Designated as safety issue: Yes ]
- Conduction disturbances [ Time Frame: 30 days, 6, 12, 24 months ] [ Designated as safety issue: Yes ]
- Various echocardiogram measurements of replacement valve functionality [ Time Frame: 30 days, 6, 12, 24 months ] [ Designated as safety issue: No ]
- NYHA Class Improvement [ Time Frame: 30 days, 6, 12, 24 months ] [ Designated as safety issue: No ]
- All Cause Mortality [ Time Frame: In hospital, 30 days, 6, 12, 24 months ] [ Designated as safety issue: Yes ]
- Cardiac Mortality [ Time Frame: In Hospital, 30 days, 6,12, 24 months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 900 |
| Study Start Date: | August 2008 |
| Estimated Study Completion Date: | September 2016 |
| Estimated Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: CoreValve® Implantation
Patients with symptomatic severe aortic stenosis who have an elevated surgical risk
|
Device: Medtronic CoreValve® System
The CoreValve® device is designed to replace the native aortic valve without the requirement for open heart surgery and without concomitant surgical removal of the failed native valve in patients with symptomatic severe aortic stenosis who have an elevated surgical risk
|
Detailed Description:
Prospective, non-randomized, single-arm multi-center trial conducted under a common protocol at 10 centers in Australia and New Zealand.
Eligibility| Ages Eligible for Study: | 65 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
- Documented severe aortic valve stenosis
- Access vessel diameter >6 mm as defined pre procedure via angiographic measure
- Aortic valve annulus diameter ≥ 20 mm and < 29 mm as defined pre procedure by echocardiographic measure
- Ascending aorta diameter ≤ 43 mm at the sino-tubular junction
Native aortic valve disease, defined as valve stenosis with an aortic valve area <1cm2 (<0.6cm2 /m2) as defined pre procedure by echocardiographic measure
AND (Assessment of Surgical Risk)
Age ≥ 80 years
OR
Surgical risk calculated with logistic EuroSCORE ≥ 20%,
OR
Age ≥ 65 years with one or two (but not more than 2) of the following criteria:
- Cirrhosis of the liver (Child class A or B)
- Pulmonary insufficiency : VMS < 1 liter
- Previous cardiac surgery (CABG, valvular surgery)
- Porcelain aorta
- Pulmonary hypertension > 60 mmHg and high probability of cardiac surgery for other than valve replacement
- Recurrent pulmonary embolus
- Right ventricular insufficiency
- Thoracic burning sequelae contraindicating open chest surgery
- History of mediastinum radiotherapy
- Severe connective tissue disease resulting in a contraindication to surgery
- Cachexia (clinical impression)
- Study subjects must be willing and able to attend all follow-up visits within specified visit windows, and agree to undergo all protocol evaluations at each visit
Exclusion Criteria:
- Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, nitinol, porcine products, or contrast media which cannot be adequately pre-medicated
- Any sepsis, including active endocarditis.
- Recent myocardial infarction (<30 days)
- Any left ventricular or atrial thrombus as determined pre procedure by echocardiography
- Uncontrolled atrial fibrillation
- Mitral or tricuspid valvular insufficiency (> grade II)
- Previous aortic valve replacement (mechanical valve or stented bioprosthetic valve)
- Evolutive or recent CVA (cerebrovascular accident), (<3 months)
- Femoral, iliac or aortic vascular condition (e.g. stenosis, tortuosity), that make impossible insertion and endovascular access to the aortic valve
- Symptomatic carotid or vertebral arteries narrowing (> 70%) disease
- Abdominal or thoracic aortic aneurysm
- Bleeding diathesis or coagulopathy, or patient will refuse blood transfusion
- Evolutive disease with life expectancy less than one year
- Creatinine clearance < 20 ml/min
- Active gastritis or known peptic ulcer disease
- Pregnancy
Contacts and Locations| Contact: Kelly Hendrickson | 763-526-3844 | kelly.hendrickson@medtronic.com |
| Australia, New South Wales | |
| St. Vincents Sydney | Recruiting |
| Darlinghurst, New South Wales, Australia | |
| Contact: Erika O'Dea +61 2 8382 2775 eodea@stvincents.com.au | |
| Principal Investigator: David Muller, MD | |
| Sub-Investigator: Paul Roy, MD | |
| Australia, Queensland | |
| Prince Charles Hospital | Recruiting |
| Chermside, Queensland, Australia | |
| Contact: Tracy McCulloch +61 7 3139 5298 tracy_mcculloch@health.qld.gov.au | |
| Contact: Maricel Roxas +61 7 3139 5906 Maricel_Roxas@health.qld.gov.au | |
| Principal Investigator: Darren Walters, MD | |
| Sub-Investigator: Con Aroney, MD | |
| Australia, South Australia | |
| Royal Adelaide Hospital | Recruiting |
| Adelaide, South Australia, Australia | |
| Contact: David Yudkin +61 8 8222 2890 David.Yudkin@health.sa.gov.au | |
| Principal Investigator: Stephen Worthley, MD | |
| Sub-Investigator: Joseph Montarello, MD | |
| Australia, Victoria | |
| Monash Hospital | Recruiting |
| Clayton, Victoria, Australia | |
| Contact: Sonia Ciavarella +61 3 9594-4543 Sonia.Ciavarella@southernhealth.org.au | |
| Principal Investigator: Ian Meredith, MD | |
| Sub-Investigator: Paul Antonis, MD | |
| St. Vincent's Melbourne | Recruiting |
| Fitzroy, Victoria, Australia | |
| Contact: Jenny Wilson +61 3 9288-4442 Jenny.Wilson@svhm.org.au | |
| Contact: Catherine Peeler +61 3 9288 4442 Catherine.Peeler@svhm.org.au | |
| Principal Investigator: Rob Whitbourn, MD | |
| Sub-Investigator: A MacIssac, MD | |
| Epworth Hospital | Recruiting |
| Melbourne, Victoria, Australia, 3004 | |
| Contact: Gerlinda Amor +61 3 9936 8050 Gerlinda.Amor@epworth.org.au | |
| Contact: Louise Lyons +61 3 9936 8052 Louise.Lyons@epworth.org.au | |
| Principal Investigator: Tony Walton, MD | |
| Sub-Investigator: Ron Dick, MD | |
| Alfred Hospital | Recruiting |
| Melbourne, Victoria, Australia | |
| Contact: Samatha Holland +61 3 9076 3269 S.Holland@alfred.org.au | |
| Principal Investigator: Tony Walton, MD | |
| Sub-Investigator: Stephen Duffy, MD | |
| Australia, Western Australia | |
| Royal Perth Hospital | Recruiting |
| Perth, Western Australia, Australia | |
| Contact: Kirrily Beer +61 8 9224 2641 kirrily.beer@health.wa.gov.au | |
| Principal Investigator: Gerald Yong, MD | |
| Sub-Investigator: Jamie Rankin, MD | |
| New Zealand | |
| Mercy Hospital | Recruiting |
| Auckland, New Zealand | |
| Contact: Rhona MacDonald +64 9630 1961 rhona@mercyangiography.co.nz | |
| Contact: Amanda Fraser +64 9630 1961 amanda@mercyangiography.co.nz | |
| Principal Investigator: John Ormiston, MD | |
| Sub-Investigator: Mark Webster, MD | |
| Waikato Hospital | Recruiting |
| Hamilton, New Zealand | |
| Contact: Liz Low +64 7 839 7136 Lizl@cardiotrialswaikato.org.nz | |
| Principal Investigator: Sanjeevan Pasaputi, MD | |
| Sub-Investigator: Gerry Devlin, MD | |
| Principal Investigator: | Ian T Meredith, MD | MonashHeart Medical Center |
| Study Director: | William Prather | Medtronic |
More Information
Publications:
| Responsible Party: | Medtronic Heart Valves |
| ClinicalTrials.gov Identifier: | NCT01015612 History of Changes |
| Other Study ID Numbers: | CV-PAVR-R2007 |
| Study First Received: | November 17, 2009 |
| Last Updated: | February 28, 2013 |
| Health Authority: | Australia: Department of Health and Ageing Therapeutic Goods Administration Australia: Human Research Ethics Committee |
Keywords provided by Medtronic Heart Valves:
|
Aortic Valve Stenosis Aortic Valve Insufficiency |
Additional relevant MeSH terms:
|
Aortic Valve Stenosis Constriction, Pathologic Heart Valve Diseases Heart Diseases |
Cardiovascular Diseases Ventricular Outflow Obstruction Pathological Conditions, Anatomical |
ClinicalTrials.gov processed this record on May 19, 2013